Alzheimer's disease: the controversial approval of Aducanumab

Neurol Sci. 2021 Aug;42(8):3069-3070. doi: 10.1007/s10072-021-05497-4. Epub 2021 Jul 29.

Authors

Fabrizio Tagliavini¹, Pietro Tiraboschi¹, Antonio Federico²

Affiliations

¹ Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
² Department Medicine, Surgery and Neurosciences, Medical School, University of Siena, Viale Bracci 2, 53100, Siena, Italy. federico@unisi.it.

PMID: 34322762
DOI: 10.1007/s10072-021-05497-4

No abstract available

Publication types

Editorial

MeSH terms

Alzheimer Disease* / drug therapy
Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized / therapeutic use
Humans

Substances

Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized
aducanumab